Clinician draft — consent discussion support. This is not a signed consent form or treatment authorisation. Review and individualise the content, then complete the approved local consent process.
Entries stay in this page’s memory and clear on reload. Do not enter names, MRNs or dates of birth. Printing or saving a PDF creates a separate document that must be handled under local policy.
1. Treatment and purpose Pertuzumab + trastuzumab maintenance · NCCP 00726 v3a
Pertuzumab and trastuzumab are given by infusion every 21 days after the chemotherapy phase of the metastatic treatment plan. Duration depends on benefit, tolerance and the agreed plan; this is not a fixed one-year adjuvant course.
Review the treatment journey, tests and phase transitions with the patient.
Individual aim, expected benefit, uncertainty and assessment plan
Reasonable alternatives, including supportive care and not proceeding with this regimen
2. Risks and supportive care Pertuzumab · HER2-targeted antibody Report diarrhoea early, especially with poor fluid intake. Keep cardiac checks and report infusion symptoms immediately.
Trastuzumab · HER2-targeted antibody Attend planned echoes. Report breathlessness, ankle swelling, rapid weight gain or infusion symptoms.
These are selected discussion prompts, not a complete risk list. Discuss serious, potentially life-threatening and lasting effects; tailor the conversation to comorbidities and the patient’s priorities. Discuss the treatment aim, alternatives, expected benefit, serious and lasting risks, fertility/pregnancy precautions, the planned monitoring and who to contact. Review the full longitudinal pathway and confirm which conditional treatments apply.
Additional material risks, individual concerns and agreed supportive plan